NCT05749042

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma :a Phase 2,Prospective, Open-label,Unicentral,Randomised Controlled Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Xin-Hua Xu · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy based of cisplatin with sintilimab as first-line therapy for patients with advanced oral cavity squamous cell carcinoma.

Conditions

• Oral Cavity Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Sintilimab	Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
RADIATION	Radiotherapy	Concurrent Chemoradiotherapy Based of Cisplatin

Timeline

• Start date: 2023-01-18
• Primary completion: 2025-01-18
• Completion: 2025-01-18
• First posted: 2023-03-01
• Last updated: 2023-03-01

Locations

1 site across 1 country: China